Travere Therapeutics Inc
TVTX
NASDAQ
Biotechnology
$62.14
USD
+0.71 (+1.16%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $5.79B
Volume 1.2M
Revenue
$591.33M
TTM
+77.1%
YoY
Gross Margin
99%
TTM
+1.8%
YoY
Net Income
$-43.46M
TTM
+74.3%
YoY
Operating Cash Flow
$92.70M
TTM
+180.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 114.4 | 164.9 | 129.7 | 127.2 | 169.6 |
YoY Growth | +111.5% | +162.1% | +73.4% | +55.6% | +48.2% |
Cost of Revenue | 1.5 | 1.6 | 2.6 | 2.0 | 2.2 |
Gross Profit | 112.9 | 163.3 | 127.1 | 125.2 | 167.4 |
Selling, General & Administrative | 62.6 | 86.5 | 101.7 | 80.3 | 96.1 |
Other Operating Expenses | 13.6 | 0.0 | 0.0 | 24.8 | 7.1 |
Total Operating Expenses | 125.6 | 138.3 | 159.6 | 162.2 | 163.5 |
Operating Income | -12.7 | 24.9 | -32.4 | -36.9 | 4.0 |
EBITDA | 1.4 | 40.7 | -14.3 | -11.7 | 8.2 |
Other Income / Expense | -0.5 | 0.5 | 11.1 | -0.1 | -40.2 |
Total Other Income / Expense | -0.1 | 0.8 | 11.4 | 0.2 | -39.0 |
Income Before Income Taxes | -12.7 | 25.7 | -21.1 | -36.7 | -35.0 |
Income Taxes | 0.0 | 0.0 | 0.9 | -0.1 | -0.2 |
Net Income | -12.8 | 25.7 | 2.7 | -37.1 | -34.8 |
Consolidated Net Income / Loss | -12.8 | 25.7 | 2.7 | -37.1 | -34.8 |
Net Income Attributable to Common Shareholders | -12.8 | 25.7 | 2.7 | -37.1 | -34.8 |
Basic EPS | -$0.14 | $0.29 | $0.03 | -$0.40 | -$0.37 |
Diluted EPS | -$0.14 | $0.28 | $0.04 | -$0.40 | -$0.37 |
Basic Shares Outstanding | 88.9M | 89.2M | 90.3M | 91.9M | 93.5M |
Diluted Shares Outstanding | 88.9M | 102.6M | 76.9M | 91.9M | 93.5M |